BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will present at the Ladenburg Thalmann 2017 Healthcare Conference in New York. Mr. Mohanty will provide an overview of the Company in his presentation on Tuesday, September 26, 2017 at 2:00 pm ET/11:00 am PT.

A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website at www.biotimeinc.com.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of the Company’s cell delivery platform is its HyStem® cell and drug delivery matrix technology. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, and one private company, AgeX Therapeutics.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170920005374/en/

Investor Contact:
BioTime
David Nakasone, 510-871-4188
[email protected]
or
Media Contact:
JQA Partners, Inc.
Jules Abraham, 917-885-7378
[email protected]

Source: BioTime, Inc.

You May Also Be Interested In

• Outward Hound Announces H.I.G. Capital as New Majority Owner to Support Next Chapter of Growth
• Teako Announces Fully Committed Private Placement
• American Mariners Protest Chinese Vessel Operating Under Jones Act Waiver in Louisiana